The initial responses to standard chemotherapies among prostate cancer (PCa) patients are
usually significant, while most of them will finally develop drug resistance, rendering them …

The insulin-like growth factor (IGF)-axis was implicated in cancer progression and identified
as a clinically important therapeutic target. Several IGF-I receptor (IGF-IR) targeting drugs …

Circulating insulin-like growth factor-1 (IGF-1) is consistently associated with prostate cancer
risk. IGF-1 binds to IGF-1 receptor (IGF1R) and insulin receptor (IR), activating cancer …

Benign prostatic hyperplasia (BPH) is characterized by non-malignant enlargement of
prostate cells causing many lower urinary tract symptoms. BPH pathogenesis includes …

Prostate cancer (PCa) is both the foremost and second cause of cancer death in the male
population. Patients with hormone‐dependent PCa are initially sensitive to androgen …

We report here a low-cost electrochemical immunoarray with unprecedented sensitivity in
the sub-zeptomole range with up to 5 log-decades dynamic range for accurate, multiplexed …

Introduction: The clinical course of prostate cancer (PCa) is highly variable, ranging from
indolent behavior to rapid metastatic progression. The Gleason score is widely accepted as …

Prostate cancer is the second most prominent form of cancer in men and confers the highest
mortality after lung cancer. The term “extracellular vesicles” refers to minute endosomal …

Prostate cancer (PCa) represents the most commonly non-cutaneous diagnosed cancer in
men worldwide and occupies a very wide area of preclinical and clinical research. Targeted …

Introduction Preclinical, clinical, and population studies have provided robust evidence for
an important role for the insulin-like growth factor (IGF) system in the development of …